Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS
- Conditions
- CoronavirusCOVID-19 Respiratory Infection
- Interventions
- Other: Sham HD-tDCSOther: Active HD-tDCS 3mA
- Registration Number
- NCT04844554
- Lead Sponsor
- Federal University of Paraíba
- Brief Summary
COVID-19 has a variety of symptoms from asymptomatic respiratory dysfunction to death. Considering the pathophysiology of SARS-CoV-2 and its relationship with the neuroimmune system, response, autonomic balance, musculoskeletal and respiratory and neuropsychiatric symptoms presented by patients, the investigators highlight the potential use of non-invasive neuromodulation methods to assess the effectiveness of treating patients with COVID-19, as these techniques can be useful in the management of important clinical aspects in the functional recovery of individuals affected by the disease.
The investigators intend to evaluate the effects of HD- tDCS to promote ventilatory weaning in patients admitted to the Intensive Care Unit (ICU) and to improve the respiratory performance of those hospitalized in nursing beds for treatment of COVID - 19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Patients of at least 18 years-old with a PCR-confirmed SARS-CoV-2 diagnosis and receiving mechanical ventilation at least 48 hours of meeting criteria for moderate to severe acute respiratory distress syndrome (ARDS), under weaning, were enrolled in this study. An ARDS diagnosis was made according to the Berlin Definition criteria.
Intensive Care Unit's
Patients were excluded if they had a condition that could prevent adequate performance of inspiratory muscle training (e.g., neuropathy or myopathy), pregnancy or active lactation, Richmond Agitation and Sedation Scale (RASS) scores between -2 and + 1, Glasgow Coma Scale (GCS) ≤ 8, consent refusal, and contraindications to brain stimulation (e.g., aneurysm clips).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 2 - Sham HD-tDCS Sham HD-tDCS Sham HD-tDCS Group 1 - 3.0 mA active HD-tDCS Active HD-tDCS 3mA HD-tDCS with 3.0 milliamperes (mA) of intensitive
- Primary Outcome Measures
Name Time Method ICU's primary outcome - number of days alive and free from mechanical ventilation 28 days The primary outcome was ventilator-free days during the first 28 days, defined as the number of days alive and free from mechanical ventilation for at least 48 consecutive hours.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Federal University of Paraíba,Department of Psychology
🇧🇷João Pessoa, Paraíba, Brazil